Pacira Pharmaceuticals Stock Five Year Return
| PCRX Stock | USD 26.51 0.01 0.04% |
Pacira Pharmaceuticals fundamentals help investors to digest information that contributes to Pacira Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Pacira Stock. The fundamental analysis module provides a way to measure Pacira Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pacira Pharmaceuticals stock.
Pacira | Five Year Return |
Pacira Pharmaceuticals Company Five Year Return Analysis
Pacira Pharmaceuticals' Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
More About Five Year Return | All Equity Analysis
Five Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Pacira Five Year Return Driver Correlations
Understanding the fundamental principles of building solid financial models for Pacira Pharmaceuticals is extremely important. It helps to project a fair market value of Pacira Stock properly, considering its historical fundamentals such as Five Year Return. Since Pacira Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacira Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacira Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.
| Competition |
Pacira Return On Tangible Assets
Return On Tangible Assets |
|
According to the company disclosure, Pacira Pharmaceuticals has a Five Year Return of 0.0%. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Pacira Five Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira Pharmaceuticals' direct or indirect competition against its Five Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Pacira Pharmaceuticals by comparing valuation metrics of similar companies.Pacira Pharmaceuticals is currently under evaluation in five year return category among related companies.
Pacira Fundamentals
| Return On Equity | 0.051 | ||||
| Return On Asset | 0.0335 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 1.54 B | ||||
| Shares Outstanding | 46.52 M | ||||
| Shares Owned By Insiders | 1.26 % | ||||
| Shares Owned By Institutions | 98.74 % | ||||
| Number Of Shares Shorted | 3.45 M | ||||
| Price To Earning | 14.34 X | ||||
| Price To Book | 1.43 X | ||||
| Price To Sales | 1.85 X | ||||
| Revenue | 674.98 M | ||||
| Gross Profit | 393.23 M | ||||
| EBITDA | 162.9 M | ||||
| Net Income | 41.95 M | ||||
| Cash And Equivalents | 316.39 M | ||||
| Cash Per Share | 6.90 X | ||||
| Total Debt | 586.04 M | ||||
| Debt To Equity | 1.10 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 18.72 X | ||||
| Cash Flow From Operations | 154.65 M | ||||
| Short Ratio | 7.57 X | ||||
| Earnings Per Share | 0.89 X | ||||
| Price To Earnings To Growth | (3.83) X | ||||
| Target Price | 46.4 | ||||
| Number Of Employees | 711 | ||||
| Beta | 0.75 | ||||
| Market Capitalization | 1.23 B | ||||
| Total Asset | 1.57 B | ||||
| Retained Earnings | (106.8 M) | ||||
| Working Capital | 412.61 M | ||||
| Current Asset | 252.58 M | ||||
| Current Liabilities | 149.79 M | ||||
| Net Asset | 1.57 B |
About Pacira Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pacira Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pacira Pharmaceuticals Investors Sentiment
The influence of Pacira Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Pacira. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Pacira Pharmaceuticals' public news can be used to forecast risks associated with an investment in Pacira. The trend in average sentiment can be used to explain how an investor holding Pacira can time the market purely based on public headlines and social activities around Pacira Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Pacira Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pacira Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Pacira Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Pacira Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pacira Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pacira Pharmaceuticals' short interest history, or implied volatility extrapolated from Pacira Pharmaceuticals options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pacira Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Pacira Pharmaceuticals Piotroski F Score and Pacira Pharmaceuticals Altman Z Score analysis. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Pacira Stock analysis
When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.291 | Earnings Share 0.89 | Revenue Per Share 14.603 | Quarterly Revenue Growth 0.054 | Return On Assets 0.0335 |
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.